MASS

In November 2025, the company reported Q3 financial results, missing EPS estimates but reaffirming its revenue outlook. In January 2026, strong preliminary Q4 and full-year results led to a stock increase. March 2026 saw the release of Q4 and full-year results, with revenue growth and positive adjusted EBITDA, along with a 2026 revenue outlook. May 2026 brought Q1 results with revenue growth but a significant EPS miss due to acquisition-related charges; the stock gained due to revenue growth and acquisitions. The acquisition of NIRLAB AG in May 2026 expanded narcotics identification capabilities and increased the revenue guidance for 2026. Analyst ratings have varied, with upgrades and downgrades, but the consensus remains a "Moderate Buy." Insider selling has been reported in April-May 2026.